Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma

J Cancer Res Clin Oncol. 2010 Jun;136(6):883-9. doi: 10.1007/s00432-009-0729-7. Epub 2009 Nov 20.

Abstract

Purpose: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) and metabolic index (MI) from fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with nasopharyngeal carcinoma (NPC).

Methods: From October 2002 to July 2004, 41 patients with NPC who underwent (18)F-FDG PET-CT scan before and after radiotherapy were reviewed retrospectively. All patients received intensity-modulated radiotherapy using 6MV X-rays. We examined the association of MTV and the results of long-term follow-up of the patients.

Results: Patients having tumors with an MTV below 30 cm(3) had significantly better 5-year overall survival (OS) (84.6:46.7%, P = 0.006) and disease-free survival (DFS) (73.1:40.0%, P = 0.014) than patients with an MTV of 30 cm(3) or greater. And the patients with MI below 130 had significantly higher 5-year OS (88.0:43.8%, P = 0.002) and DFS (76.0:37.5%, P = 0.005) than other patients. In the Cox multivariate analysis, MI and metabolic response (MR) were predictive of DFS, and we did not find a significant relationship between standard uptake value (SUV) and OS or DFS.

Conclusions: The present study shows that tumor volume parameters, especially the combination of MTV and SUV in the "metabolic index", are valuable for predicting long-term survival. High MI may be useful for identifying patients requiring more aggressive treatment.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / diagnosis*
  • Carcinoma / diagnostic imaging
  • Carcinoma / metabolism
  • Carcinoma / pathology
  • Carcinoma / therapy
  • Chemotherapy, Adjuvant
  • Cisplatin / administration & dosage
  • Disease-Free Survival
  • Dose Fractionation, Radiation
  • Female
  • Fluorodeoxyglucose F18*
  • Fluorouracil / administration & dosage
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Nasopharyngeal Neoplasms / diagnosis*
  • Nasopharyngeal Neoplasms / diagnostic imaging
  • Nasopharyngeal Neoplasms / metabolism
  • Nasopharyngeal Neoplasms / pathology
  • Nasopharyngeal Neoplasms / therapy
  • Neoplasm Staging
  • Positron-Emission Tomography* / methods
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • ROC Curve
  • Radiopharmaceuticals
  • Radiotherapy, Adjuvant
  • Radiotherapy, Intensity-Modulated*
  • Retrospective Studies
  • Sample Size
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed* / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Cisplatin
  • Fluorouracil